Panitumumab: 6 agencies, 2008–2017
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused panitumumab: all 5 decisive outcomes across 2 agencies were positive or positive with restrictions.
Assessment has run over 8.9 years, from 30 Apr 2008 at HAS (France) to 8 Mar 2017 at HAS (France).
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for panitumumab, 2 submissions were never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
Nothing has been added since 2017; on this evidence the file is dormant.
Against its own class, panitumumab is an outlier: 100% of its decisive outcomes were positive, where molecules sharing ATC class L01X average 75%.
6 distinct indication wordings are recorded for panitumumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 11 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess panitumumab, on 30 Apr 2008; PBAC (Australia) did not open a file until 2015 — a wide spread of 7.2 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 6 years in total.
3 of the 6 agencies here assessed panitumumab more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for panitumumab.
The full ledger for panitumumab reads 5 recommended, 2 non-submission, 1 superseded and 1 advice, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 8 Mar 2017 | Indication extension | SMR substantial | source |
| AWMSG (Wales) | 16 Jul 2015 | First-line treatment in combination with FOLFOX or FOLFIRI for adult patients with wild-type RAS metastatic colorectal c… | superseded (non-submission) | source |
| SMC (Scotland) | 13 Jul 2015 | Treatment of adult patients with wild-type RAS metastatic colorectal cancer first-line in combination with FOLFIRI. | not recommended | source |
| PBAC (Australia) | 2015 | Metastatic colorectal cancer | The PBAC recommended the first-line listing of panitumumab, for the treatment of RAS wild-… | source |
| ZIN (Netherlands) | 23 Mar 2015 | Pakketadvies panitumumab (Vectibix®) bij gemetastaseerd coloncarcinoom | advice published | source |
6 further decisions for panitumumab, across 4 agencies, are not shown here. They link to 3 further source documents.
Related molecules
- cetuximab — divergent outcome (recommended vs not recommended) on a shared indication
- trifluridine — divergent outcome (recommended vs not recommended) on a shared indication
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
Coverage: 11 decisions for panitumumab from 6 agencies, 2008 to 2017. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.